Order ZstatFlu®.
		ZymeTx, Inc. is a biotechnology company engaged in the comprehensive discovery and development of products for the diagnosis and treatment of infectious viruses. The company's major disease targets include influenza, parainfluenza, herpes simplex (HSV), respiratory syncytial virus (RSV) and cytomegalovirus (CMV). ZymeTx has the clinically proven ability to identify and characterize enzymes critical to the viral disease process then synthesize and patent novel compounds that interact selectively with these enzymes. Highly specific diagnostic and therapeutic compounds are derived from this research approach. The company has received 8 Food and Drug Administration (FDA) clearances for its products. The ZymeTx research and development laboratories emerged from the Oklahoma Medical Research Foundation (OMRF). ZymeTx, Inc. (Nasdaq: ZMTX) completed a public offering of its common stock November 9, 1997 raising $21.8 million in gross proceeds. In the offering, 2,645,000 common shares were issued. The prospectus for the offering is available on-line in a PDF format. Past and current press releases are available along with a bibliography of major publications referencing the company or it's products. The NASDAQ stock quote for the company along with SEC filings in a PDF or DOC format are also available at this site.
			ZymeTx Web Sites: zymetx.com flu101.com fluwatch.com ©2003 - ZymeTx, Inc. ZstatFlu®, ViraZyme®, and ViraSTAT® are trademarks of ZymeTx, Inc.